Safety of Lorlatinib in ALK-Positive Non-Small-Cell Lung Cancer and Management of Central Nervous System Adverse Events

References

• Sung H , FerlayJ, SiegelRLet al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Azelby CM , SakamotoMR, BowlesDW. ROS1 targeted therapies: current status. Curr. Oncol. Rep.23(8), 94 (2021).
   PubMed Web of Science ®Google Scholar
• Pirker R , FilipitsM. From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer. ESMO Open4(5), e000548 (2019).
   PubMed Web of Science ®Google Scholar
• El Darsa H , Abdel-RahmanO, SanghaR. Pharmacological and clinical properties of lorlatinib in the treatment of ALK-rearranged advanced non-small cell lung cancer. Expert Opin. Pharmacother.21(13), 1547–1554 (2020).
   PubMed Web of Science ®Google Scholar
• Hochmair MJ , FabikanH, IlliniOet al. Later-line treatment with lorlatinib in ALK- and ROS1-rearrangement-positive NSCLC: a retrospective, multicenter analysis. Pharmaceuticals (Basel)13(11), 371 (2020).
   PubMedGoogle Scholar
• Syed YY . Lorlatinib: first global approval. Drugs79(1), 93–98 (2019).
   PubMed Web of Science ®Google Scholar
• Choo JR , SooRA. Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer. Expert Rev. Anticancer. Ther.20(4), 233–240 (2020).
   PubMed Web of Science ®Google Scholar
• Cooper AJ , SequistLV, LinJJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat. Rev. Clin. Oncol.19(8), 499–514 (2022).
   PubMed Web of Science ®Google Scholar
• Yang J , GongW. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer. Expert Rev. Clin. Pharmacol.12(3), 173–178 (2019).
   PubMed Web of Science ®Google Scholar
• Chen W , JinD, ShiY, ZhangY, ZhouH, LiG. The underlying mechanisms of lorlatinib penetration across the blood–brain barrier and the distribution characteristics of lorlatinib in the brain. Cancer Med.9(12), 4350–4359 (2020).
   PubMed Web of Science ®Google Scholar
• Chen J , O’GormanMT, JamesLP, KlamerusKJ, MugunduG, PithavalaYK. Pharmacokinetics of lorlatinib after single and multiple dosing in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer: results from a global phase I/II study. Clin. Pharmacokinet.60(10), 1313–1324 (2021).
   PubMed Web of Science ®Google Scholar
• Lin S , GongJ, CanasGCet al. A phase I study to evaluate the pharmacokinetics and safety of lorlatinib in adults with mild, moderate, and severe renal impairment. Eur. J. Drug Metab. Pharmacokinet.47(2), 235–245 (2022).
   PubMed Web of Science ®Google Scholar
• Peng L , ZhuL, SunYet al. Targeting ALK rearrangements in NSCLC: current state of the art. Front. Oncol.12, 863461 (2022).
   PubMed Web of Science ®Google Scholar
• Solomon BJ , BesseB, BauerTMet al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol.19(12), 1654–1667 (2018).
   PubMed Web of Science ®Google Scholar
• Felip E , ShawAT, BearzAet al. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann. Oncol.32(5), 620–630 (2021).
   PubMed Web of Science ®Google Scholar
• Shaw AT , BauerTM, de MarinisFet al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N. Engl. J. Med.383(21), 2018–2029 (2020).
   PubMed Web of Science ®Google Scholar
• Solomon BJ , BauerT, MokTet al. Updated efficacy and safety from the phase 3 CROWN study of first-line lorlatinib vs crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Cancer Res.82(Suppl. 12), CT223 (2022).
   Web of Science ®Google Scholar
• Solomon BJ , BauerTM, MokTSKet al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir. Med.11(4), 354–366 (2023).
   PubMed Web of Science ®Google Scholar
• Descourt R , PérolM, Rousseau-BussacGet al. Brigatinib for pretreated, ALK-positive, advanced non-small-cell lung cancers: long-term follow-up and focus on post-brigatinib lorlatinib efficacy in the multicenter, real-world BrigALK2 study. Cancers (Basel)14(7), 1751 (2022).
   PubMed Web of Science ®Google Scholar
• Lee J , SunJM, LeeSHet al. Efficacy and safety of lorlatinib in Korean non-small-cell lung cancer patients with ALK or ROS1 rearrangement whose disease failed to respond to a previous tyrosine kinase inhibitor. Clin. Lung Cancer20(3), 215–221 (2019).
   PubMed Web of Science ®Google Scholar
• Kılıçkap S , DemirciU, BuğdaycıFet al. Lorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: experience from an early access program in Turkey. J. Thorac. Oncol.14(10), S558–S559 (2019).
   Google Scholar
• Frost N , ChristopoulosP, Kauffmann-GuerreroDet al. Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. Ther. Adv. Med. Oncol.13, 1758835920980558 (2021).
   Web of Science ®Google Scholar
• Guérin A , SasaneM, ZhangJet al. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. J. Med. Econ.18(4), 312–322 (2015).
   PubMed Web of Science ®Google Scholar
• Bauer TM , ShawAT, JohnsonMLet al. Brain penetration of lorlatinib: cumulative incidences of CNS and non-CNS progression with lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer. Target. Oncol.15(1), 55–65 (2020).
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I , OxnardGR, EvangelistMet al. Phase II study of lorlatinib in patients with anaplastic lymphoma kinase-positive lung cancer and CNS-specific relapse. JCO Precis. Oncol.6, e2100522 (2022).
   PubMed Web of Science ®Google Scholar
• Ando K , ManabeR, KishinoYet al. Comparative efficacy and safety of lorlatinib and alectinib for ALK-rearrangement positive advanced non-small cell lung cancer in Asian and non-Asian patients: a systematic review and network meta-analysis. Cancers (Basel)13(15), 3704 (2021).
   PubMed Web of Science ®Google Scholar
• Nagasaka M , OuSI. Lorlatinib should be considered as the preferred first-line option in patients with advanced ALK-rearranged NSCLC. J. Thorac. Oncol.16(4), 532–536 (2021).
   PubMed Web of Science ®Google Scholar
• Ma HC , LiuYH, DingKLet al. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials. BMC Cancer21(1), 1278 (2021).
   PubMed Web of Science ®Google Scholar
• Wang L , ShengZ, ZhangJet al. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis. J. Chemother.34(2), 87–96 (2022).
   PubMed Web of Science ®Google Scholar
• Ando K , ManabeR, KishinoYet al. Comparative efficacy of ALK inhibitors for treatment-naïve ALK-positive advanced non-small cell lung cancer with central nervous system metastasis: a network meta-analysis. Int. J. Mol. Sci.24(3), 2242 (2023).
   PubMed Web of Science ®Google Scholar
• Peng Y , ZhaoQ, LiaoZ, MaY, MaD. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: a systematic review and network meta-analysis. Cancer129(8), 1261–1275 (2023).
   PubMed Web of Science ®Google Scholar
• Seto T , HayashiH, SatouchiMet al. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study. Cancer Sci.111(10), 3726–3738 (2020).
   PubMed Web of Science ®Google Scholar
• Bauer TM , FelipE, SolomonBJet al. Clinical management of adverse events associated with lorlatinib. Oncologist24(8), 1103–1110 (2019).
   PubMed Web of Science ®Google Scholar
• Lu S , ZhouQ, LiuXet al. Lorlatinib for previously treated ALK-positive advanced non-small cell lung cancer: primary efficacy and safety from a phase 2 study in China. J. Thorac. Oncol.17(6), 816–826 (2022).
   PubMed Web of Science ®Google Scholar
• Mogenet A , TomasiniP, GreillierL, BarlesiF. Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?Transl. Lung Cancer Res.8(Suppl. 4), S383–S386 (2019).
   PubMedGoogle Scholar
• Yun KM , BazhenovaLA. Update on lorlatinib: role in reducing the risk of disease progression in ALK-positive NSCLC. Cancer Manag. Res.14, 843–850 (2022).
   PubMed Web of Science ®Google Scholar
• Reed M , RosalesAS, ChiodaMD, ParkerL, DevganG, KettleJ. Consensus recommendations for management and counseling of adverse events associated with lorlatinib: a guide for healthcare practitioners. Adv. Ther.37(6), 3019–3030 (2020).
   PubMed Web of Science ®Google Scholar
• Barata F , AguiarC, MarquesTR, MarquesJB, HespanholV. Monitoring and managing lorlatinib adverse events in the Portuguese clinical setting: a position paper. Drug Saf.44(8), 825–834 (2021).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency . Summary of product characteristics (Lorviqua). www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf
   Google Scholar
• Nagasaka M , GeY, SukariA, KukrejaG, OuSI. A user’s guide to lorlatinib. Crit. Rev. Oncol. Hematol.151, 102969 (2020).
   PubMed Web of Science ®Google Scholar
• Peled N , GillisR, KilickapSet al. GLASS: global lorlatinib for ALK(+) and ROS1(+) retrospective study: real world data of 123 NSCLC patients. Lung Cancer148, 48–54 (2020).
   PubMed Web of Science ®Google Scholar
• Chabrol A , MayengaM, HamidAMet al. Lorlatinib-induced pulmonary arterial hypertension. Lung Cancer120, 60–61 (2018).
   PubMed Web of Science ®Google Scholar
• Toyozawa R , HaratakeN, ToyokawaGet al. Lorlatinib-induced pulmonary embolism in a patient with an ALK-positive NSCLC. JTO Clin. Res. Rep.1(2), 100005 (2020).
   PubMedGoogle Scholar
• Lee CS , WanchooR, SeetharamuN. Lorlatinib induced proteinuria: a case report. J. Oncol. Pharm. Pract.27(4), 1037–1039 (2021).
   PubMed Web of Science ®Google Scholar
• Desai A , SriwastavaS, GadgeelSM, LisakRP. New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent. J. Neurol. Sci.392, 100–101 (2018).
   PubMed Web of Science ®Google Scholar
• Solomon BJ , BauerTM, IgnatiusOu SHet al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study. J. Clin. Oncol.JCO2102278 (2022).
   Google Scholar
• Dagogo-Jack I , AbbattistaA, MurphyJFet al. Factors associated with developing neurocognitive adverse events in patients receiving lorlatinib after progression on other targeted therapies. J. Thorac. Oncol.18(1), 67–78 (2023).
   PubMed Web of Science ®Google Scholar
• National Cancer Institute . Common Terminology Criteria for Adverse Events, Version 3.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf
   Google Scholar
• Peters S , ShawAT, BesseBet al. Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. Lung Cancer144, 10–19 (2020).
   PubMed Web of Science ®Google Scholar